



A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia

Carolina B. Lobato^{1,2}, Sofia S. Pereira^{1,2,3,4}, Marta Guimarães^{1,2,5}, Bolette Hartmann^{6,7}, Nicolai J. Wewer Albrechtsen^{6,7,8}, Linda Hilsted⁸, Jens J. Holst^{6,7}, Mário Nora^{1,5} and Mariana P. Monteiro^{1,2*}

¹ Endocrine, Cardiovascular & Metabolic Research, Unit for Multidisciplinary Research in Biomedicine (UMIB), University of Porto, Porto, Portugal, ² Department of Anatomy, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal, ³ Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto, Porto, Portugal, ⁴ Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal, ⁵ Department of General Surgery, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal, ⁶ Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, ⁷ Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, ⁸ Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

OPEN ACCESS

Edited by:

Zoltan Pataky,
Geneva University Hospitals (HUG),
Switzerland

Reviewed by:

Thomas Alexander Lutz,
University of Zurich, Switzerland
Angelo Tremblay,
Laval University, Canada

*Correspondence:

Mariana P. Monteiro
mpmonteiro@icbas.up.pt

Specialty section:

This article was submitted to
Obesity,
a section of the journal
Frontiers in Endocrinology

Received: 19 September 2020

Accepted: 22 October 2020

Published: 30 November 2020

Citation:

Lobato CB, Pereira SS, Guimarães M, Hartmann B, Wewer Albrechtsen NJ, Hilsted L, Holst JJ, Nora M and Monteiro MP (2020) A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia. *Front. Endocrinol.* 11:608248. doi: 10.3389/fendo.2020.608248

Obesity and obesity-related diseases are major public health concerns that have been exponentially growing in the last decades. Bariatric surgery is an effective long-term treatment to achieve weight loss and obesity comorbidity remission. Post-bariatric hypoglycemia (PBH) is a late complication of bariatric surgery most commonly reported after Roux-en-Y gastric bypass (RYGB). PBH is the end result of postprandial hyperinsulinemia but additional endocrine mechanisms involved are still under debate. Our aim was to characterize entero-pancreatic hormone dynamics associated with postprandial hypoglycemia after RYGB. Individuals previously submitted to RYGB ($N=23$) in a single tertiary hospital presenting PBH symptoms (*Sym*, $n=14$) and asymptomatic weight-matched controls (*Asy*, $n=9$) were enrolled. Participants underwent a mixed-meal tolerance test (MMTT) to assess glucose, total amino acids (total AA), insulin, C-peptide, glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and neurotensin (NT). We found that hypoglycemia during the MMTT was equally frequent in *Sym* and *Asy* groups ($p=1.000$). Re-grouped according to glucose nadir during the MMTT (*Hypo* $n=11$ vs *NoHypo* $n=12$; nadir <3.05 mmol/l vs ≥ 3.05 mmol/l), subjects presented no differences in anthropometric (BMI: $p=0.527$) or metabolic features (HbA_{1c}: $p=0.358$), yet distinct meal-elicited hormone dynamics were identified. Postprandial glucose excursion and peak glucose levels were similar ($p>0.05$), despite distinct late glycemic outcomes ($t=60$ min and $t=90$ min: $p<0.01$), with overall greater glycemic variability in *Hypo* group (minimum-to-maximum glucose ratio: $p<0.001$). *Hypo* group meal-triggered hormone profile was characterized by lower early glucagon ($t=15$ min: $p<0.01$) and higher insulin ($t=30$ min: $p<0.05$, $t=45$ min: $p<0.001$), C-peptide ($t=30$ min: $p<0.01$, $t=45$ min: $p<0.001$, $t=60$ min: $p<0.05$), and GLP-1 ($t=45$ min: $p<0.05$) levels. Hyperinsulinemia was an independent

risk factor for hypoglycemia ($p < 0.05$). After adjusting for hyperinsulinemia, early glucagon correlated with glycemic nadir ($p < 0.01$), and prevented postprandial hypoglycemia ($p < 0.05$). A higher insulin to glucagon balance in *Hypo* was observed ($p < 0.05$). No differences were observed in total AA, GIP or NT excursions ($p > 0.05$). In sum, after RYGB, postprandial hyperinsulinemia is key in triggering PBH, but a parallel and earlier rise in endogenous glucagon might sustain the inter-individual variability in glycemic outcome beyond the effect of hyperinsulinism, advocating a potential pivotal role for glucagon in preventing hyperinsulinemic hypoglycemia.

Keywords: glucagon, glucagon-like peptide-1, hyperinsulinemia, hypoglycemia, Roux-en-Y gastric bypass

INTRODUCTION

Bariatric surgery is the most effective long-term treatment for obesity and related disorders (1). Despite the health benefits from weight loss surgical interventions, post-bariatric patients management is essential to avoid nutrient deficiencies as well as for timely detection of other less frequent surgical or medical complications (1).

Meal-triggered hypoglycemia can occur after several upper gastrointestinal surgical procedures (2, 3). A reduction in postprandial glucose nadir has also been reported after non-surgical weight loss interventions (4–6). Post-bariatric hypoglycemia (PBH) is a late complication of bariatric surgery (7), for which there is a lack of consensus on diagnostic criteria, since etiology is still a matter of debate (2).

Postprandial hyperinsulinemia is a common finding and considered to be the ultimate trigger of postprandial hypoglycemia (7). However, the leading cause for the hyperinsulinemia observed remains to be elucidated. Structural pancreatic changes, such as nesidioblastosis, insulinoma or other insulinotropic neuroendocrine tumors, responsible for autonomous hyperinsulinemia are rarely found to be the cause (8), although these entities must be ruled out before assuming PBH diagnosis (9). Alternatively, altered gut hormone dynamics (10, 11) or lack of putative unidentified “anti-incretin” factors (12) were also hypothesized to have a role in triggering the hyperinsulinemic response observed in PBH.

The fact that PBH frequency can be mitigated by dietary interventions (2, 13, 14) and pharmacological interventions that reduce carbohydrate digestion or absorption, delay gastro-intestinal transit time, limit insulin secretion or suppress incretin effects (10, 15, 16), suggests a role for entero-pancreatic hormone dynamics in this condition.

Thus, the goal of this study was to characterize the entero-pancreatic hormone dynamics associated with PBH in patients previously submitted to Roux-en-Y gastric bypass (RYGB).

MATERIALS AND METHODS

Patient Selection

Participants were recruited from our single center cohort of post-bariatric patients submitted to RYGB by the same surgical team using a standardized technical procedure as previously described

(17). Patients enrolled in the study ($N=23$) included subjects that spontaneously reported autonomic and neuroglycopenic symptoms suggestive of PBH, (*Sym*, $n=14$; reported as “Self-reported hypoglycemia symptoms” in **Table 1**), matched to asymptomatic surgical controls (*Asy*, $n=9$) recruited from the patient cohort under routine follow-up at our center. Reports of sweating, tremor, palpitations, anxiety, hunger, or paresthesia/tingling were recognized as autonomic symptoms, while headache, slurred speech, drowsiness, weakness, visual disturbances, concentration difficulties, confusion, seizures, or altered consciousness were assumed as neuroglycopenic symptoms (2). All participants reporting consistently at least one of the previous symptoms at enrolment were allocated into the *Sym* group. Inclusion criteria comprised previous RYGB surgery, being weight stable—defined as less than 10% body weight variation over the previous 6 months—and having an HbA1c $< 6.5\%$ and fasting plasma glucose < 7.0 mmol/l at the time of screening visit. Exclusion criteria were current pregnancy, taking glucose-lowering drugs or prior diagnosis of any medical condition that could be responsible for hypoglycemia after comprehensive workout.

The study protocol was reviewed and approved Local Institutional Ethics Committee (Comissão de Ética para a Saúde CHEDV, Epe). Patients provided their written informed consent to participate in this study. No potentially identifiable human images or data is presented in this study.

Study Design

After an overnight 12-h fast, patients underwent a mixed-meal tolerance test (MMTT) with a standardized liquid meal (Fresubin Energy Drink, 200 ml, 300 kcal [50E% carbohydrate, 15E% protein and 35E% fat]; Fresenius Kabi Deutschland, Bad Homburg, Germany), based on macronutrient composition in accordance to post-bariatric surgery nutritional recommendations, as well as to allow comparisons with previous studies (15, 17). Patients were instructed to abstain from alcohol consumption and strenuous physical activity the day before trial-days. Patients were requested to slowly drink the liquid meal over the first 15 min of the MMTT (grey shade in Figures), to assure consistency among subjects.

Peripheral venous blood sampling was performed using EDTA tubes (S-Monovette® 9.0 ml, K2 EDTA Gel, 1.6 mg/ml, Sarstedt) at pre-established timepoints before and after the start of meal ingestion (baseline and 15, 30, 45, 60, 90, and 120 min), with simultaneous monitoring of pulse and blood pressure (BP).

TABLE 1 | Anthropometric, demographic and metabolic features of post-RYGB patients according to glucose profile during the MMTT (*Hypo* and *NoHypo*).

	MMTT result		p value
	Hypo	NoHypo	
N (% of total)	11 (47.8%)	12 (52.2%)	NA
Sex (male/female)	2/9	2/10	1.000
Age at surgery (years)	40.6 (32.5–48.5)	45.2 (39.0–47.8)	0.294
History of T2DM before surgery (yes/no)	0/11	3/9	0.217
Follow-up time after surgery (years)	5.1 ± 0.6	3.8 ± 0.7	0.159
BMI before surgery (kg/m ²)	40.1 ± 1.5	41.5 ± 1.6	0.527
BMI after surgery (kg/m ²)	27.6 ± 0.7	28.5 ± 1.0	0.502
%EBMIL (%)	83.2 ± 4.0	81.9 ± 6.1	0.864
%TWL (%)	30.6 ± 2.1	31.0 ± 2.1	0.884
HbA1c (mmol/mol)	34.4 ± 1.3	35.8 ± 1.0	0.365
HbA1c (%)	5.3 ± 0.1	5.4 ± 0.1	0.358
HOMA2-B (%)	77.9 ± 6.7	70.1 ± 5.6	0.376
HOMA2-S (%)	144.2 ± 11.6	152.3 ± 15.6	0.685
HOMA2-IR	0.8 (0.6–0.8)	0.6 (0.5–1.0)	0.618
Self-reported hypoglycemia symptoms (yes/no)	7/4	7/5	1.000
Dumping criteria (yes/no)	11/0	10/2	0.478

Results are presented as mean ± SEM, median (interquartile range) or proportions. MMTT, mixed-meal tolerance test; *Hypo*, individuals developing a glucose nadir <3.05 mmol/l during the MMTT; *NoHypo*, subjects with glucose levels ≥3.05 mmol/l during MMTT; T2DM, type 2 diabetes mellitus; BMI, body mass index; EBMIL, excess BMI loss; TWL, total weight loss; HOMA2-B, homeostasis model assessment for β -cell function; HOMA2-S, homeostasis model assessment for insulin sensitivity; HOMA2-IR, homeostasis model assessment for insulin resistance.

Samples were kept refrigerated until separation and plasma was stored at -20°C until analyzed.

Study Groups

Study subjects were recruited and initially grouped according to symptomatic status at presentation (*Sym*, *n*=14 and *Asy*, *n*=9). Subjects were then re-allocated into two different groups according to the glucose profile during the MMTT, into an *Hypo* (*n*=11) group, including patients with a glycemic nadir <3.05 mmol/l (<55 mg/dl) during the MMTT, and a *NoHypo* (*n*=12) group, comprising the participants with glucose ≥3.05 mmol/l (≥55 mg/dl) during the entire test.

Biochemical Measurements

Whole blood glucose was assessed using a commercially available glucometer (Freestyle Precision Neo Glucose meter, Abbott, USA). Plasma insulin and C-peptide levels were measured by electrochemiluminescence sandwich immunoassay (ECLIA) (Cobas 8000, model e602, Roche Diagnostics, USA), against two liquid human serum-based controls: LiquechekTM Immunoassay Plus Control, Level 1 #361 and Level 3 #363, Bio-Rad for insulin and LiquechekTM Specialty Immunoassay Control, Level 1 #364 Level 3 #366, Bio-Rad for C-peptide. Other plasma hormone levels were quantified by radioimmunoassay (RIA), using analytical methods previously described (17), namely glucagon, with no cross-reactivity with GLP-1, glicentin, or oxyntomodulin (antibody code no 4305) (18), total glucose-dependent insulinotropic polypeptide (GIP) (antibody code no 867) (19), total glucagon-like peptide-1 (GLP-1) (antibody code no 89390) (20) and neurotensin (NT) (antibody code no 3D97) (21). Sensitivity for all assays was below 1 pmol/l and intra-assay coefficient of variation below 10%. Total amino acids (total AA) were assayed as previously described (22) in plasma samples from 19 subjects (*Hypo* *n*=8 and *NoHypo* *n*=11).

Calculations

Percentage of total weight loss (%TWL) and of excess body mass index (BMI) loss (%EBMIL) were determined, respectively, as [(preoperative weight – weight at MMTT) ÷ (weight at MMTT) × 100] and [(preoperative BMI – BMI at MMTT) ÷ (preoperative BMI – 25) × 100], with 25 kg/m² as target BMI.

Updated homeostasis model assessment indexes (HOMA2) were determined using the HOMA Calculator version 2.2.3 (<http://www.dtu.ox.ac.uk>, accessed April 2018) as surrogate measures of beta cell function (HOMA2-B) and peripheral insulin sensitivity (HOMA2-S) and resistance (HOMA2-IR).

A pulse rise greater than 10 beats per minute during the first 30 min of the provocative test was assumed to be a sensitive and specific early dumping sign (23) and referred to as “Dumping criteria”.

Incremental area under the curve (iAUC) was calculated using the trapezoidal rule, with deduction of the fasting hormonal levels from the subsequent time points. To assess glycemic variability, minimum-to-maximum glucose ratio (MMGR) was calculated as the ratio from maximum to minimum glycemic values observed during the MMTT. Insulinogenic index (IGI) was calculated by the ratio of incremental C-peptide from fasting to 30 min of the MMTT to glycemia variation in the same time window. Oral glucose insulin sensitivity (OGIS) was determined (24, 25) and multiplied with IGI to calculate the Disposition Index, as a measure of insulin secretion adjusted for insulin sensitivity. Insulin secretion rate (ISR) was obtained from C-peptide plasma levels (CV 5%) with adjustment for sex, age and BMI by ISEC program (26). Insulin clearance was then retrieved from tAUC_{ISR}/tAUC_{insulin}. Insulin: glucagon ratio (IGR) was used to assess the variance between catabolic and anabolic responses to the meal-stimulus (27). A gut hormone incretin/glucagon ratio was post-hoc computed as the product of GLP-1 and GIP divided by glucagon levels (GLP-1*GIP/Glucagon).

Statistical Analysis

Statistical analysis was performed using the GraphPad Prism version 8.0.1 for Windows (GraphPad Software, La Jolla California USA). Correlations and logistic regressions were performed with IBM® SPSS® Statistics version 25 for Windows. Differences between the two groups were considered statistically significant when p value was below 0.05.

Normality of continuous variables was assessed using the D'Agostino & Pearson test. For normally distributed variables, the two groups were compared using unpaired two-tailed t -test and results are presented as mean $\pm$ standard error of the mean (SEM). Variables that do not follow a normal distribution are represented as median (interquartile range) and were compared using Mann-Whitney test. To assess dynamic changes during the MMTT, changes of hormones and metabolites between time points were compared using a two-way ANOVA with Sidak's *post hoc* test. Categorical variables are expressed as proportions and were compared by Fisher's exact test.

Preliminary bivariate Spearman's rho correlations were performed between postprandial hormonal excursions (glucagon, insulin, GLP-1, GIP, and NT) and glycemic nadir during MMTT (not-Gaussian distributed). For variables that correlated with the glycemic nadir ($p < 0.05$), partial correlations and binary logistic regressions were performed to assess whether these correlations were independent and to disclose the potential of hormone excursions to predict hypoglycemia respectively.

RESULTS

Subject Anthropometric and Clinical Features

Subject groups initially enrolled on the basis of self-reported symptoms suggestive of PBH (*Sym*, $n=14$) or as asymptomatic controls (*Asy*, $n=9$) presented no significant differences in anthropometric, demographic and metabolic features (Supplementary Table 1). Glycemic profiles ($iAUC_{0-120}$: $p=0.214$) during the MMTT were not significantly different between the two participants groups. In addition, the frequency of postprandial hypoglycemia during the MMTT was similar in two groups, with 50.0% (7 of 14) of the *Sym* and 44.4% (4 of 9) of the *Asy* individuals developing hypoglycemia ($p=1.000$, Supplementary Table 1).

Based on the glycemic response during the MMTT, study participants were then re-grouped into *Hypo* group (glucose nadir < 3.05 mmol/l, $n=11$) or *NoHypo* (glucose ≥ 3.05 mmol/l during MMTT, $n=12$).

Demographic Data

There were no differences in anthropometric or demographic features between *Hypo* and *NoHypo* subjects. Three individuals had been diagnosed with type 2 diabetes (T2DM) prior to RYGB but were in remission and off any glucose lowering medications at study entry (HbA1c = 5.2%, 5.9%, and 5.5%, 2.1, 2.6, and 8.2

years after RYGB, respectively). None of the patients with T2DM prior to RYGB presented glucose nadir < 3.05 mmol/l during the MMTT (*NoHypo*) (Table 1).

Comparing biochemical profiles of *Hypo* and *NoHypo* groups, there were no differences in fasting glucose, HbA1c levels and surrogate measures for beta cell function (HOMA2-B), hepatic insulin sensitivity (HOMA2-S) and peripheral insulin resistance (HOMA2-IR) ($p > 0.05$, Table 1), which were also within the normal physiological intervals (28).

Glucose, Total Amino Acids, and Hormone Profiles During MMTT

Hypo and *NoHypo* groups presented distinctive glycemic profiles, particularly at 60 and 90 min of the MMTT ($p=0.003$ and $p=0.002$ respectively), with *Hypo* group presenting a glucose peak ($p=0.049$) and nadir ($p < 0.001$) 11% and 38% lower, respectively. *Hypo* subjects also presented a 40% higher glycemic variability (MMGR: $p < 0.001$) (Table 2, Figure 1A). Total AA excursion during MMTT was not significantly different in the two study groups ($p > 0.05$) (Table 2, Figure 1B). No differences in vasoactive response, as assessed by pulse rate and BP curves, were observed ($p > 0.05$, data not shown).

Hypo and *NoHypo* groups depicted significantly different hormone profiles along the MMTT, despite no significant differences at baseline were observed. Insulin and co-secreted C-peptide postprandial levels were significantly higher in *Hypo* group (insulin $t=30$ min: $p=0.015$ and $t=45$ min: $p < 0.001$; C-peptide $t=30$ min: $p=0.008$, $t=45$ min: $p < 0.001$, and $t=60$ min: $p=0.018$) and throughout the MMTT ($iAUC$: $p=0.019$), yielding a significantly higher Disposition Index ($p=0.005$), IGI ($p=0.007$), and ISR ($iAUC_{0-120}$: $p=0.002$; 15–30 and 30–45 min: $p < 0.001$), even when adjusted for glucose excursion ($ISR_{iAUC}/Glucose_{iAUC}$: $p=0.034$) (Table 2, Figures 2B–D). Hyperinsulinemia (insulin $iAUC_{0-45}$), with plasma insulin peak levels twice higher in the *Hypo* group (Figure 2B), was a risk for hypoglycemia during MMTT (binary logistic regression: $p=0.042$). Insulin excursion ($iAUC_{0-45}$) was inversely correlated with glycemic nadir even when adjusted for the effect of early glucagon excursion (partial correlation: $r=-0.475$, $p=0.026$).

In *NoHypo* group, peak glucagon levels occurred earlier and were significantly higher when compared to *Hypo* ones (15 min: $p=0.002$, Figure 2A). Early glucagon excursion (glucagon levels at 15 min time point of the MMTT) was associated with the risk of later hypoglycemia (binary logistic regression: $p=0.045$) and correlated positively with glycemic nadir, even after suppressing postprandial hyperinsulinemia effect (partial correlation: $r=0.628$, $p=0.002$).

Higher post-peak GLP-1 levels were observed in *Hypo* when compared to *NoHypo* group (45 min: $p=0.049$, Figure 3A). There were no significant differences in GIP (Figure 3B) and NT (Figure 3C) profiles between the study groups.

IGR was increased throughout the MMTT in the *Hypo* group ($iAUC$: $p=0.011$, Figure 4A). Peak incretin/glucagon ratio, computed from GLP-1, GIP, and glucagon levels, was found to be significantly higher in *Hypo* group (30 min: $p=0.008$, Figure 4B).

TABLE 2 | Meal induced glucose and hormone responses in post-RYGB patients according to MMTT glycemic response (*Hypo* and *NoHypo*).

	MMTT result		<i>p</i> value
	<i>Hypo</i>	<i>NoHypo</i>	
N (% of total)	11 (47.83)	12 (52.17%)	NA
Glucose			
Fasting (mmol/l)	4.5 ± 0.1	4.7 ± 0.3	0.324
iAUC _{0-120'} (mmol/l x min)	223.5 ± 13.2	263.7 ± 27.5	0.214
Peak (mmol/l)	8.5 ± 0.3	9.6 ± 0.4	0.049
Nadir (mmol/l)	2.5 ± 0.1	4.0 ± 0.3	<0.001
MMGR	3.5 ± 0.2	2.5 ± 0.1	<0.001
Total AA			
Fasting (μmol/l)	1394 ± 151.7	1396 ± 141.5	0.992
iAUC _{0-120'} (μmol/l x min)	92400 ± 16433	95334 ± 12932	0.889
Insulin			
Fasting (pmol/l)	40.9 (29.4–45.7)	32.8 (27.2–52.9)	0.576
iAUC _{0-120'} (nmol/l x min)	99.1 (60.8–113.8)	45.4 (37.4–53.6)	0.019
IGI	44.4 (32.8–54.6)	24.9 (16.6–36.2)	0.007
OGIS [ml/(min x m ²)]	395.9 (380.3–448.1)	401.6 (376.6–424.2)	0.695
Disposition Index	17646.2 ± 1385.6	10848.6 ± 1630.5	0.005
C-peptide			
Fasting (pmol/l)	492.3 (435.5–602.9)	505.0 (375.1–544.8)	0.910
iAUC _{0-120'} (nmol/l x min)	235.7 ± 17.2	168.4 ± 15.3	0.008
ISR			
Fasting [pmol/(kg.min)]	1.7 (1.5–2.0)	1.6 (1.3–1.8)	0.518
iAUC _{0-120'} (pmol/kg)	1016 ± 67.3	694.2 ± 60.3	0.002
ISR _{iAUC} /Glucose _{iAUC}	323.5 ± 23.7	226.3 ± 34.8	0.034
Insulin Clearance			
Fasting	3.0 ± 0.2	3.4 ± 0.3	0.369
Postprandial _{0-120'}	0.8 (0.7–1.0)	1.2 (0.8–1.7)	0.079
Glucagon			
Fasting (pmol/l)	5.8 ± 0.8	6.3 ± 0.8	0.695
iAUC _{0-120'} (pmol/l x min)	869.3 ± 121.3	758.3 ± 124.8	0.532
GLP-1			
Fasting (pmol/l)	21.1 ± 2.5	14.8 ± 2.4	0.080
iAUC _{0-120'} (pmol/l x min)	7717 ± 958.1	6558 ± 725.3	0.341
GIP			
Fasting (pmol/l)	4.0 (3.0–6.0)	6.0 (2.6–9.0)	0.384
iAUC _{0-120'} (pmol/l x min)	4298 (3353–5689)	3683 (2607–5665)	0.339
Neurotensin			
Fasting (pmol/l)	20.0 (18.0–24.0)	20.0 (20.0–27.0)	0.653
iAUC _{0-120'} (pmol/l x min)	13440 (8940–20100)	12765 (10774–18764)	0.833

Results are presented as mean ± SEM or median (interquartile range). Statistically significant differences (*p* value <0.05) are highlighted in bold. MMTT, mixed-meal tolerance test; *Hypo*, individuals developing a glucose nadir <3.05 mmol/l during the MMTT; *NoHypo*, subjects with glucose levels ≥3.05 mmol/l during MMTT; MMGR, minimum-to-maximum glucose ratio; Total AA, total amino acids; IGI, insulinogenic index; OGIS, oral glucose insulin sensitivity; iAUC, postprandial incremental AUC; ISR, insulin secretion rate; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1.


DISCUSSION

This study provides insights into hormonal dynamics involved in PBH occurring as a late complication of interventions, as RYGB (2). During a provocative meal test, a positive correlation between early postprandial glucagon excursion and later glycemic nadir was identified, disclosing a potential role for glucagon in preventing hypoglycemia.

To conduct this study, subjects submitted to RYGB that spontaneously reported symptoms suggestive of hypoglycemia and asymptomatic controls underwent a mixed meal test. Our herein study was designed to assess the hormonal dynamics prompting hypoglycemia. Hence the test duration was set on 120 min, rather a longer duration that would be required to assess counterregulatory responses to hypoglycemia (29).

A glucose cut-off value of 3.05 mmol/l was selected to define hypoglycemia, in line with previous studies (10, 11, 15). In response to the meal stimulus, postprandial hypoglycemia occurred in a similar proportion in *Sym* and *Asy* groups, as previously reported (30). Thus, our findings further support that the occurrence of reactive hypoglycemia per se during a provocative meal test is not useful to diagnose PBH in patients presenting suggestive symptoms.


Diagnosing PBH poses several challenges that span from the clinical manifestations to diagnostic test selection and interpretation. The very first obstacle is symptoms under- or mis-reporting, due to partial overlap with dumping syndrome and/or hypoglycemia unawareness (31–33). While we have previously shown that self-reported symptoms compatible with PBH might be useful for PBH diagnosis when paired along concurrent flash glucose monitoring




data, caution shall be taken when considering symptoms alone for PBH diagnosis (33). Our current data reinforces the limited value of symptom reports, as no correlation was observed between symptoms and the glucose profile prompted by a standardized meal stimulus. In the face of our findings, authors advise against establishing PBH diagnosis solely based on patient symptom reports.

Moreover, postprandial hypoglycemia is highly dependent on meal composition, size and texture (2, 13). So, despite the use of standardized macronutrient-balanced meal stimulus, there is no guaranty that a given meal will be able to replicate the conditions leading to PBH in each individual patient or provide clinically useful information.

After this initial observation, subjects were re-allocated according to glucose profile during the meal test into two new groups depending on the occurrence of postprandial hypoglycemia or not (*Hypo* and *NoHypo*). No differences in clinical features that could provide possible explanations for a distinct glucose meal test response to the same stimulus were found between subjects of





Hypo and *NoHypo* groups. Then, the hormone dynamics that ultimately lead to postprandial hypoglycemia were analyzed.


There are several levels of evidence in support of the role of gut-hormone dynamics in triggering PBH (7). RYGB produces major modifications in gut anatomy that invariably increase the rate of intestinal nutrient exposure (34, 35) and occasionally interfere with vagus nerve integrity potentially compromising autonomic pancreatic and gastro-intestinal innervation (36, 37). In order to minimize the impact of anatomical diversity on gut hormone responses, only subjects that underwent a standardized procedure performed by the same surgical team were enrolled in this study (17). During the meal test, no significant differences in meal-triggered vasoactive response (pulse and BP, data not shown) were observed between subject groups. Hence, suggesting no major variations in gastric emptying rate although not formally assessed.

Nevertheless, subjects with meal-triggered hypoglycemic response had higher postprandial insulin and C-peptide excursions, without altered insulin sensitivity or beta-cell function, thus, reinforcing the role of hyperinsulinism, with peak levels 2-times higher, as the central mechanism of PBH (8, 10).

Furthermore, our results suggest that a postprandial glucagon excursion preceding insulin peak might increase glucose levels at nadir, thus preventing hypoglycemia. Indeed, glucagon was proposed to be involved in several physiological actions beyond the classical insulin counter regulatory actions namely mediating the liver-alfa cell axis (11, 38). Therefore, the hypothesis that early glucagon response “primes” the liver to maintain a sustained glucose production relevant at later time points after the meal stimulus cannot be excluded. Moreover, when insulin and glucagon levels were combined in the IGR, lower IGR (27) was observed in the group without hypoglycemia, suggesting a catabolic status with increased hepatic glucose output and further stressing hypothesis. In a previous study by Tharakan et al, higher glucagon levels 30 min after a meal were associated with higher rates of later postprandial hypoglycemia, which led the authors to propose that pancreatic glucagon might contribute to an exaggerated insulin response (11). However, in our study, an even earlier glucagon response 15 min after the meal was associated with lower rates of postprandial hypoglycemia, suggesting a protective role against hypoglycemia. The fact that the “protective” glucagon peak was observed 15 min after meal, while in the previous study glucagon levels were first evaluated only 30 min after the meal, could provide an explanation for the differences observed.

Still, despite this early glucagon excursion it should be noticed that a late phase glucagon response to a glucose lowering trend was also observed, along with insulin, C-peptide and incretins’ hormone suppression, in line with the well described glucagon counter-regulatory role (10, 38).

After RYGB, the exaggerated postprandial glucagon excursion in response to a mixed-meal was previously reported (11, 35, 39). However, the anatomical origin and mechanisms leading to postprandial glucagon excursion in these patients are not fully disclosed. In fact, glucagon secretion was expected to be suppressed by the simultaneous high glucose and GLP-1 levels (40), although not observed. Post-prandial glucagon could be



secreted either by intestinal L-cells (38, 41) or by cephalic phase release from pancreatic alpha cells (42). Indeed, a subset of L-cells co-secreting GLP-1 and glucagon was identified in subjects after RYGB, but not before surgery (39). Overall, these factors could contribute to modify GLP-1 and glucagon secretion patterns, although these hypotheses require to be confirmed. The physiological stimulus for postprandial glucagon secretion is also a matter of debate. In addition to hypoglycemia, amino acids are known to play a pivotal role in glucagon secretion (38). After RYGB, earlier intestinal amino acid absorption is reported to lead to higher and more precocious postprandial amino acid plasma levels (43). Since no major differences in total amino acids postprandial profiles were observed between groups, our data does not support an amino acid contribution for the early glucagonemic response observed. Nevertheless, specific glucagonotropic amino acid levels, namely of alanine, tyrosine

or glutamine, which might provide further insights into amino acids-glucagon dynamics, were not measured (44). Thus, despite total amino acid excursions did not provide evidence supporting a potential role for amino acids in prompting the differential glucagon excursions, it cannot be ruled out since the individual amino acids' levels were not quantified.

The next question is what to expect from a higher glucagon response. Historically, according to the glucostatic theory of appetite control, one could predict that postprandial hyperglucagonemia observed after weight loss would not only prevent hypoglycemia and raise glycemic nadir, but also reduce hunger and suppress food intake, thus contributing to sustain weight loss (5, 6). However, PBH is usually associated with weight regain (45). Nevertheless, the potential use of glucagon for treating patients with PBH was tested using low-dose closed-loop infusion pumps that demonstrated to reduce the rates of hypoglycemia and prevent rebound hyperglycemia (16).

GLP-1 and GIP are incretin hormones with well-demonstrated insulinotropic effects (40). In the present study, to minimize the impact of active hormone levels interindividual variability derived from variable dipeptidyl peptidase 4 (DPP4) activity according to individuals' weight and circulating insulin levels (46), total GLP-1 and GIP levels were measured. Subjects that developed postprandial hypoglycemia presented higher postprandial GLP-1 levels, consistent with some (2, 11) but not all previous reports (30).

The demonstration that blocking GLP-1 receptor with exendin 9-39 could mitigate the occurrence of postprandial hypoglycemia (10, 47) lead the authors to hypothesize that GLP-1 had a relevant role in mediating PBH. In contrast, in our study the finding that GLP-1 levels preceding insulin peak were similar in the two groups does not support a central role for GLP-1 in triggering the distinct hyperinsulinemic response. Moreover, no significant correlation between GLP-1 levels and later hypoglycemia was found. Similarly, no significant differences in fasting or postprandial GIP levels were observed between the groups to suggest a direct involvement in mediating PBH, a finding that is consistent with prior observations (11). Nevertheless, the GLP-1 insulinotropic potential is well-established and the possibility that a mismatch between different hormonal excursions and the timepoints considered cannot be ruled out and might sustain the similarities observed for postprandial excursions. Lastly, since GIP was demonstrated to induce glucagon secretion a potential contribution cannot be fully excluded nor confirmed (48).

In an attempt to infer the putative impact of the combined action of the different hormones that influence glucose dynamics, taking into account the GLP-1 and GIP insulinogenic action (40) and the counter regulatory effect of glucagon (38), an incretin/glucagon ratio was computed. This post-hoc exploratory analysis derived from the hypothesis that PBH is the end result of the unbalance between early endogenous glucagon insulin-antagonistic effect and insulinotropic stimuli. Indeed, our results support our hypothesis by revealing a higher incretin/glucagon ratio in those patients that develop postprandial hypoglycemia.

This study presents some limitations that must be acknowledged. This was an exploratory observational study which included a relatively small sample of patients submitted to RYGB at a single hospital institution, therefore limiting data extrapolations to other types of bariatric surgery interventions or mechanistic interpretations. Additionally, subjects had no dietary restrictions imposed on the days prior to the meal challenge, which could have influenced the meal response. Moreover, the larger time intervals between hormone assessments after the 60 min timepoints against the performed in early postprandial period, in addition to the 120 min for the total duration of the meal test precluded a more detailed evaluation of the hormone dynamics. The panel of hormones measured did not include counter regulatory hormones, such as cortisol and growth hormone, which could have limited the characterization of all endocrine pathways involved. Finally, the incretin/glucagon ratio herein computed for the first time with the rationale of assessing the balance between hormones known to influence postprandial glycemia, still requires further validation. Nevertheless, this study major strength is to provide insights into the early gut-pancreatic hormone dynamics associated with PBH, unravelling the importance of glucagon and incretin/glucagon balance, thus setting the grounds for further research over the molecular pathways leading to PBH.

Our study provides novel insights into the potential role of glucagon in preventing postprandial hypoglycemia, which may contribute to devising targeted medical or surgical interventions to prevent and manage PBH.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors upon justified request, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Local Institutional Ethics Committee (Comissão de Ética para a Saúde CHEDV, Epe). The patients/participants provided their written informed consent to participate in this study.

REFERENCES

1. Fried M, Yumuk V, Oppert JM, Scopinaro N, Torres A, Weiner R, et al. Interdisciplinary European guidelines on metabolic and bariatric surgery. *Obes Surg* (2014) 24(1):42–55. doi: 10.1007/s11695-013-1079-8
2. Eisenberg D, Azagury DE, Ghiassi S, Grover BT, Kim JJ. ASMBS Position Statement on Postprandial Hyperinsulinemic Hypoglycemia after Bariatric Surgery. *Surg Obes Relat Dis* (2017) 13(3):371–8. doi: 10.1016/j.soard.2016.12.005
3. Van der Kleij F, Vecht J, Lamers C, Masclee A. Diagnostic value of dumping provocation in patients after gastric surgery. *Scand J Gastroenterol* (1996) 31(12):1162–6. doi: 10.3109/00365529609036905
4. Tremblay A, Doucet E, Imbeault P, Mauriege P, Despres JP, Richard D. Metabolic fitness in active reduced-obese individuals. *Obes Res* (1999) 7(6):556–63. doi: 10.1002/j.1550-8528.1999.tb00714.x

AUTHOR CONTRIBUTIONS

CL, SP, MG, MN, and MM were responsible for study conception and design. CL, MG, SP, BH, NW, and LH performed experiments. CL and SP analyzed data. CL, SP, MG, MN, JH, and MM interpreted results of experiments. CL prepared figures and drafted the manuscript. SP, MG, BH, NW, LH, JH, MN, and MM edited and revised it critically for relevant intellectual content. All authors contributed to the article and approved the submitted version. MM is the guarantor of this work.

FUNDING

Unit for Multidisciplinary Research in Biomedicine (UMIB) is funded by the Foundation for Science and Technology (FCT) Portugal (grant numbers UID/MULTI/0215/2016, UID/Multi/00215/2019, UIDB/00215/2020, and UIDP/00215/2020). JH holds an unrestricted grant from the Novo Nordisk Foundation Center for Basic Metabolic Research, Copenhagen, Denmark. The NNF Foundation Center for Basic Metabolic Research is an independent research institution at the University of Copenhagen, Denmark.

ACKNOWLEDGMENTS

Authors thank the study participants for volunteering to join this study and complying with the investigation protocol. Authors also acknowledge the Senior Nurses Sandra Tavares and Andreia Ferreira (Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal) for their technical assistance during the MMTT; and Lene B. Albæk (Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark) and Lene Ravn (Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark) for their technical assistance with assays.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fendo.2020.608248/full#supplementary-material>

5. Tremblay A, Sauve L, Despres JP, Nadeau A, Theriault G, Bouchard C. Metabolic characteristics of postobese individuals. *Int J Obes* (1989) 13(3):357–66.
6. Boule NG, Chaput JP, Doucet E, Richard D, Despres JP, Bouchard C, et al. Glucose homeostasis predicts weight gain: prospective and clinical evidence. *Diabetes Metab Res Rev* (2008) 24(2):123–9. doi: 10.1002/dmrr.768
7. Salehi M, Vella A, McLaughlin T, Patti ME. Hypoglycemia After Gastric Bypass Surgery: Current Concepts and Controversies. *J Clin Endocrinol Metab* (2018) 103(8):2815–26. doi: 10.1210/je.2018-00528
8. Dirksen C, Eiken A, Bojsen-Moller KN, Svane MS, Martinussen C, Jorgensen NB, et al. No Islet Cell Hyperfunction, but Altered Gut-Islet Regulation and Postprandial Hypoglycemia in Glucose-Tolerant Patients 3 Years After Gastric Bypass Surgery. *Obes Surg* (2016) 26(9):2263–7. doi: 10.1007/s11695-016-2197-x

9. Guimaraes M, Rodrigues P, Pereira SS, Nora M, Goncalves G, Albrechtsen NW, et al. GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass. *Endocrinol Diabetes Metab Case Rep* (2015) 2015:150049. doi: 10.1530/EDM-15-0049
10. Craig CM, Liu LF, Deacon CF, Holst JJ, McLaughlin TL. Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia. *Diabetologia* (2017) 60(3):531–40. doi: 10.1007/s00125-016-4179-x
11. Tharakan G, Behary P, Wewer Albrechtsen NJ, Chahal H, Kenkre J, Miras AD, et al. Roles of increased glycemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass. *Eur J Endocrinol* (2017) 177(6):455–64. doi: 10.1530/EJE-17-0446
12. Salinari S, Mingrone G, Bertuzzi A, Previti E, Capristo E, Rubino F. Down-regulation of Insulin Sensitivity After Oral Glucose Administration: Evidence for the “Anti-Incretin Effect”. *Diabetes* (2017) 66(11):2756–63. doi: 10.2337/db17-0234
13. Stano S, Alam F, Wu L, Dutia R, Ng SN, Sala M, et al. Effect of meal size and texture on gastric pouch emptying and glucagon-like peptide 1 after gastric bypass surgery. *Surg Obes Relat Dis* (2017) 13(12):1975–83. doi: 10.1016/j.soard.2017.09.004
14. Marques AR, Lobato CB, Pereira SS, Guimaraes M, Faria S, Nora M, et al. Insights from the Impact of Meal Composition on Glucose Profile Towards Post-bariatric Hypoglycemia Management. *Obes Surg* (2019) 30:249–55. doi: 10.1007/s11695-019-04147-1
15. Ohrstrom CC, Worm D, Hojager A, Andersen D, Holst JJ, Kielgast UL, et al. Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide. *Diabetes Obes Metab* (2019) 21(9):2142–51. doi: 10.1111/dom.13796
16. Mulla CM, Zavitsanos S, Laguna Sanz AJ, Pober D, Richardson L, Walcott P, et al. A Randomized, Placebo-Controlled Double-Blind Trial of a Closed-Loop Glucagon System for Post-Bariatric Hypoglycemia. *J Clin Endocrinol Metab* (2019) 105(4):e1260–71. doi: 10.1210/clinem/dgz197
17. Patricio BG, Morais T, Guimaraes M, Veedfald S, Hartmann B, Hilsted L, et al. Gut hormone release after gastric bypass depends on the length of the biliopancreatic limb. *Int J Obes (Lond)* (2018) 43:1009–18. doi: 10.1038/s41366-018-0117-y
18. Orskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. *J Clin Invest* (1991) 87:415–23. doi: 10.1172/JCI115012
19. Krarup T, Holst JJ. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. *Regul Pept* (1984) 9:35–46. doi: 10.1016/0167-0115(84)90005-3
20. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. *Diabetes* (1994) 43:535–9. doi: 10.2337/diabetes.43.4.535
21. Pedersen JH, Stadil F, Fahrenkrug J. Preparation of 125I-(Tyr 3)- and 125I-(Tyr 11)-neurotensin for radioimmunoassay. *Scand J Clin Lab Invest* (1983) 43:483–91. doi: 10.1080/00365518309168435
22. Wewer Albrechtsen NJ, Junker AE, Christensen M, Haedersdal S, Wibrand F, Lund AM, et al. Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes. *Am J Physiol Gastrointest Liver Physiol* (2018) 314(1):G91–G6. doi: 10.1152/ajpgi.00216.2017
23. Scarpellini E, Arts J, Karamanolis G, Laurenus A, Siquini W, Suzuki H, et al. International consensus on the diagnosis and management of dumping syndrome. *Nat Rev Endocrinol* (2020) 16:448–66. doi: 10.1038/s41574-020-0357-5
24. Bojsen-Møller KN, Dirksen C, Svane MS, Jorgensen NB, Holst JJ, Richter EA, et al. Variable reliability of surrogate measures of insulin sensitivity after Roux-en-Y gastric bypass. *Am J Physiol Regul Integr Comp Physiol* (2017) 312(5):R797–805. doi: 10.1152/ajpregu.00291.2016
25. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. *Diabetes Care* (2001) 24(3):539–48. doi: 10.2337/diacare.24.3.539
26. Hovorka R, Soons PA, Young MA. ISEC: a program to calculate insulin secretion. *Comput Methods Programs Biomed* (1996) 50(3):253–64. doi: 10.1016/0169-2607(96)01755-5
27. Unger RH. Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses. *Diabetes* (1971) 20(12):834–8. doi: 10.2337/diab.20.12.834
28. Ghasemi A, Tohidi M, Derakhshan A, Hashemini M, Azizi F, Hadaegh F. Cut-off points of homeostasis model assessment of insulin resistance, beta-cell function, and fasting serum insulin to identify future type 2 diabetes: Tehran Lipid and Glucose Study. *Acta Diabetol* (2015) 52(5):905–15. doi: 10.1007/s00592-015-0730-3
29. Rebelos E, Moriconi D, Scalese M, Denoth F, Molinaro S, Siciliano V, et al. Impact of Postprandial Hypoglycemia on Weight Loss After Bariatric Surgery. *Obes Surg* (2020) 30(6):2266–73. doi: 10.1007/s11695-020-04465-9
30. Emous M, van den Broek M, Wijma R, de Heide LJM, Laskewitz A, van Dijk G, et al. Prevalence of hypoglycaemia in a random population after Roux-en-Y gastric bypass after a meal test. *Endocr Connect* (2019) 8(7):969–78. doi: 10.1530/EC-19-0268
31. Halperin F, Patti ME, Skow M, Bajwa M, Goldfine AB. Continuous glucose monitoring for evaluation of glycemic excursions after gastric bypass. *J Obes* (2011) 2011:869536. doi: 10.1155/2011/869536
32. Kefurt R, Langer FB, Schindler K, Shakeri-Leidenmuhler S, Ludvik B, Prager G. Hypoglycemia after Roux-En-Y gastric bypass: detection rates of continuous glucose monitoring (CGM) versus mixed meal test. *Surg Obes Relat Dis* (2015) 11(3):564–9. doi: 10.1016/j.soard.2014.11.003
33. Lobato CB, Pereira SS, Guimarães M, Morais T, Oliveira P, de Carvalho JPM, et al. Use of flash glucose monitoring for post-bariatric hypoglycaemia diagnosis and management. *Sci Rep* (2020) 10(1):11061. doi: 10.1038/s41598-020-68029-8
34. Dirksen C, Damgaard M, Bojsen-Møller KN, Jorgensen NB, Kielgast U, Jacobsen SH, et al. Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux-en-Y gastric bypass. *Neurogastroenterol Motil* (2013) 25(4):346–e255. doi: 10.1111/nmo.12087
35. Svane MS, Bojsen-Møller KN, Martinussen C, Dirksen C, Madsen JL, Reitelsted S, et al. Postprandial Nutrient Handling and Gastrointestinal Secretion of Hormones After Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. *Gastroenterology* (2019) 156(6):1627–41.E1. doi: 10.1053/j.gastro.2019.01.262
36. Salehi M, Gastaldelli A, D'Alessio DA. Role of vagal activation in postprandial glucose metabolism after gastric bypass in individuals with and without hypoglycaemia. *Diabetes Obes Metab* (2019) 21(6):1513–7. doi: 10.1111/dom.13676
37. van Wezenbeek MR, van Oudheusden TR, Smulders JF, Nienhuijs SW, Luyer MD. Transection versus preservation of the neurovascular bundle of the lesser omentum in primary Roux-en-Y gastric bypass surgery. *Surg Obes Relat Dis* (2016) 12(2):283–9. doi: 10.1016/j.soard.2015.07.019
38. Knop FK. EJE PRIZE 2018: A gut feeling about glucagon. *Eur J Endocrinol* (2018) 178(6):R267–R80. doi: 10.1530/EJE-18-0197
39. Jorsal T, Wewer Albrechtsen NJ, Christensen MM, Mortensen B, Wandall E, Langholz E, et al. Investigating Intestinal Glucagon after Roux-en-Y Gastric Bypass Surgery. *J Clin Endocrinol Metab* (2019) 104(12):6403–16. doi: 10.1210/jc.2019-00062
40. Monteiro MP, Batterham RL. The Importance of the Gastrointestinal Tract in Controlling Food Intake and Regulating Energy Balance. *Gastroenterology* (2017) 152(7):1707–17. doi: 10.1053/j.gastro.2017.01.053
41. Lund A, Bagger JJ, Wewer Albrechtsen NJ, Christensen M, Grondahl M, Hartmann B, et al. Evidence of Extraparacrine Glucagon Secretion in Man. *Diabetes* (2016) 65(3):585–97. doi: 10.2337/db15-1541
42. Veedfald S, Plamboeck A, Deacon CF, Hartmann B, Knop FK, Vilsbøll T, et al. Cephalic phase secretion of insulin and other enteropancreatic hormones in humans. *Am J Physiol Gastrointest Liver Physiol* (2016) 310(1):G43–51. doi: 10.1152/ajpgi.00222.2015
43. Bojsen-Møller KN, Jacobsen SH, Dirksen C, Jorgensen NB, Reitelsted S, Jensen JE, et al. Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. *Am J Clin Nutr* (2015) 102(3):600–7. doi: 10.3945/ajcn.115.109298
44. Wewer Albrechtsen NJ, Faerch K, Jensen TM, Witte DR, Pedersen J, Mahendran Y, et al. Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids. *Diabetologia* (2018) 61(3):671–80. doi: 10.1007/s00125-017-4535-5
45. Suhl E, Anderson-Haynes SE, Mulla C, Patti ME. Medical nutrition therapy for post-bariatric hypoglycemia: practical insights. *Surg Obes Relat Dis* (2017) 13(5):888–96. doi: 10.1016/j.soard.2017.01.025

46. Silva Júnior WS, Souza M, Nogueira Neto JF, Bouskela E, Kraemer-Aguiar LG. Dipeptidyl Peptidase 4 Activity Is Related to Body Composition, Measures of Adiposity, and Insulin Resistance in Subjects with Excessive Adiposity and Different Degrees of Glucose Tolerance. *J Diabetes Res* (2019) 2019:5238013. doi: 10.1155/2019/5238013
47. Salehi M, Gastaldelli A, D'Alessio DA. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. *Gastroenterology* (2014) 146(3):669–80. doi: 10.1053/j.gastro.2013.11.044
48. Lund A, Vilsboll T, Bagger JJ, Holst JJ, Knop FK. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. *Am J Physiol Endocrinol Metab* (2011) 300(6): E1038–46. doi: 10.1152/ajpendo.00665.2010

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Lobato, Pereira, Guimarães, Hartmann, Wewer Albrechtsen, Hilsted, Holst, Nora and Monteiro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.